Study Title:

Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience

Study Abstract

There is considerable evidence for the role of low-density lipoprotein cholesterol (LDL-C) in the development of atherosclerotic cardiovascular disease. Although statin therapy remains the most frequency prescribed medication to reduce LDL-C and lower risk of cardiovascular disease, a considerable number of patients develop muscle-related side affects. This review summarizes recent literature supporting the role of nutraceuticals as LDL-C-lowering therapy in statin-intolerant patients, with evidence from our own clinical practices.

Study Information

Clin Cardiol . 2018 Jan;41(1):159-165. doi: 10.1002/clc.22862. Epub 2018 Jan 24.

Full Study

https://pubmed.ncbi.nlm.nih.gov/29363784/